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The International Symposium on Leish-
maniasis Vaccines, held in Olinda, Brazil,
on March 9–11, 2009, congregated inter-
national experts who conduct research on
vaccines against the leishmaniases. The
questions that were raised during that
meeting and the ensuing discussions are
compiled in this report and may assist in
guiding a research agenda. A group to
further discussion on issues raised in this
policy platform has been set up at http://
groups.google.com/group/leishvaccines-l.
The Impact of the
Leishmaniases and Perspectives
for Anti-Leishmania Vaccines
The leishmaniases areresponsible for the
second-highest number of deaths due to
parasitic infection globally and are over-
whelmingly associated with poverty [1].
They have an estimated prevalence of 12
million humans infected and cause a
burden estimated at 2,357,000 disability-
adjusted life years [1]. Visceral leishmani-
asis(VL)isalmostalwaysfatalifnottreated,
and morbidity caused by the cutaneous
leishmaniases (CLs) is also important.
Treatments for all forms of leishmaniases
are few, toxic, and/or expensive, and,
furthermore, drug resistance is on the rise
[2]. Canids are significant zoonotic reser-
voirsforhumanVL(theirrole asa reservoir
for other species of Leishmania is not fully
defined [3]) and a cause of concern for
owners of dogs; they are also important
sources of knowledge about the human
counterparts of this infection. Leishmania-
ses are vector-borne diseases, and the
impact of global warming on the geograph-
ical distribution of parasite-infected sand
flies suggests that the leishmaniases may
become a widespread and significant prob-
lem for public health. Political and socio-
economic changes may have an even more
important role than global warming on the
changing epidemiology of the leishmania-
ses, as has been argued for tick-borne
diseases in Europe [4]. Indeed, in the last
20 years in Brazil, the epidemiological
pattern of VL has changed from a sporadic
disease of rural areas to one occurring in
peri-urban epidemics that affect all socio-
economic strata, and with a trend towards
increasing mortality [5]. The European
Centre for Disease Prevention and Control
lists the leishmaniases among the ten
vector-borne diseases that have the greatest
potential to affect European inhabitants
[6]. The leishmaniases are, so far, not
preventable diseases, and their epidemio-
logical profile is shifting. This current
situation demands novel instruments for
treatment and control.
The feasibility of controlling the leish-
maniases with a vaccine, a likely cost-
effective approach for their control in
many epidemiological situations, is attested
to by the fact that most individuals who
were once infected and recovered are
resistant to overt clinical manifestations
upon re-infections [7]. There are, however,
still many challenges to overcome before
effective vaccines for prevention of the
leishmaniases become a reality. The cen-
turies-old practice of leishmanization,
which uses inoculation of live, virulent
Leishmania major parasites at cosmetically
acceptable sites of the body, affords lifelong
protection against CL and represents the
only efficacious vaccine for any disease of
this complex [8]; its correlates of protection
should be exhaustively explored.
Regarding product profiles, if a live
vaccine proves to be the only successful
route to controlling the leishmaniases,
issues of logistics will certainly arise.
However, this aspect has not prevented
two other live vaccines to eradicate one
disease (smallpox) and almost eradicate
another (polio). Product profiles, in turn,
directly affect research strategies and clin-
ical development, but should not abort
research on useful antigens that otherwise
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profile. At present there is no consensus
about the product profile for vaccines
against the leishmaniases, except the min-
imum requirements for neglected parasitic
diseases: safe, effective, and inexpensive.
Mechanisms of Protective
Immunity
In animal models, immunity against
Leishmania has historically been cast within
the Th1/Th2 paradigm. Cellular immu-
nity is considered to be the key mediator
of resistance by means of IFN-c, which
upregulates the production of nitric oxide,
leading to oxidative burst in phagocytes
that harbor these intracellular pathogens.
However, evidence of Th2 and T regula-
tory responses in resistant mice, and
progressive disease in resistant strains that
have defects in Th1 differentiation but do
not default to a Th2 pathway, has led to a
modification of this paradigm to state that
a Th2 response does not promote disease,
but the absence of Th1 immunity does [9].
In addition, the discovery of IL-10-medi-
ated regulation of protective IFN-c-pro-
ducing cells has shown that a highly
regulated Th1 response can also lead to
susceptibility [10]. The Th1 immune
response can also be associated with
immunopathology; for example, develop-
ment of lesions in human tegumentary
leishmaniasis is due to activation of type 1
immune responses. Moreover, individuals
infected with L. braziliensis but who do
not develop disease produce less type 1
cytokines than patients with cutaneous
lesions [11]. Studies must be done to
determine whether such individuals did
not develop disease because they had small
Th1 immune responses or because they
received a low dose of antigen.
The precise role of antibodies in con-
ferring resistance to infections with Leish-
mania is controversial and needs to be
reappraised. The role of antibodies in
tuberculosis, caused by an intracellular
pathogen, was also controversial. Howev-
er, recent work shows that antibodies
participate in important effector mecha-
nisms in the response against tuberculosis
[12]. Antibodies also regulate the outcome
of immune responses through different
types of Fc receptors [13]. Animals lacking
B cells are resistant to infections with
Leishmania [14], and the elevated levels of
IgG seen in human and canine VL suggest
that antibodies are not relevant for pro-
tection in the absence of an appropriate
cellular response. More recent work,
however, supports a role of antibodies in
protection against Leishmania. Natural an-
tibodies in normal human sera have been
shown to very rapidly kill infective culture
promastigotes by the classical pathway of
complement [15]. Sera from dogs vacci-
nated against L. infantum with LiESAp
antigen killed promastigotes and amasti-
gotes and inhibited the in vitro infectivity
of promastigotes for canine macrophages
[16]. Mice lacking IgG1 are more resistant
to L. mexicana infection and mount a strong
IgG2a/c antibody response [17]. L. major
Figure 1. Number of Leishmania vaccine trials in last three decades. Data are derived from Table S1, which contains a summary of all vaccines
to date (both experimental and in clinical use). Black bars represent CL: L. major, L. mexicana, L. tropica, L. amazonensis, and L. braziliensis; gray bars
represent VL: L. donovani, L. chagasi, and L. infantum.
doi:10.1371/journal.pntd.0000943.g001
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produces different outcomes of infection:
mice infected with IgG-opsonized para-
sites showed enhanced protective immu-
nity as well as increased numbers of L.
major–infected lesional dendritic cells, lead-
ing to production of IL-12 and priming of
Th1 and Tc1 cells and efficient parasite
killing by lesional macrophages [18].
C57BL/6 mice co-infected with L. amazo-
nensis and L. major develop chronic disease
and produce less antigen-specific antibod-
ies compared to similarly co-infected
C3HeB/FeJ mice, which heal [19]. These
and other results indicate that the subclass,
specificity, and, possibly, affinity of anti-
Leishmania antibodies may determine out-
come of infection.
Kedzierski and colleagues [20] caution
against extrapolating results obtained with
the murine models of immunity to hu-
mans: there are still no unambiguous
correlates of protection, and the induction
of a putatively protective IFN-c response
via vaccines will not be sufficient to induce
protection if levels of IL-10 are dispropor-
tionately elevated. They propose that
testing for IL-10 is as important as testing
for IFN-c to determine whether a vaccine
has induced protective responses. So far
the leishmanin (Montenegro) skin test is
the most informative and practical immu-
nological surrogate marker used in clinical
trials [21]. With a complementary ratio-
nale Campos-Neto [22] has shown that
disease-associated Th2 antigens of Leish-
mania can be protective if a Th1 response
to them is generated before infection.
Moreover, the immune response to a
given antigen (e.g., LACK) can be protec-
tive (Th1) or exacerbating (Th2), depend-
ing on the way the antigen is introduced
[23] or on the genetic background of the
mouse. More recently, Nyle ´n and Akuffo
[24] proposed a strategy to search for the
different biomarkers of outcomes of infec-
tion with Leishmania parasites in human
subjects. These biomarkers may be essen-
tial not only for elucidating details of
protective immunity, but for determining
the efficacy of vaccines and for assisting in
screening of novel antigens. This same
approach is now also guiding research on
AIDS vaccines [25]. The focus on indi-
viduals with infection but no clinical
manifestations is logical because while
natural immunity against Leishmania may
not prevent infection, the fact that the
majority of infections do not result in
disease indicates that efficacious immune
mechanisms exist. This situation is seen in
dogs [26], and more emphasis should be
given to canine immunology. This natural
protective response should be the gold
standard, and the development and
efficacy of vaccines should be considered
within the context of this standard.
Persistence of Parasites: Role in
Immunity Vaccine Development
Leishmanization is unacceptable for
many individuals and regulatory agencies
Figure 2. Profile of strategies used in leishmaniasis trials. Data are derived from Table S1, which contains a summary of all vaccines to date
(both experimental and in clinical use). Bar graphs display the number of trials for each Leishmania species and the type of antigens that have been
tested.
doi:10.1371/journal.pntd.0000943.g002
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complications and is potentially problem-
atic in immunocompromised recipients;
however, co-injection of live parasites with
CpG oligodeoxynucleotides attenuates the
severity of disease following leishmaniza-
tion in mice [27]. Vaccination with live
parasites that harbor suicide cassettes,
making them susceptible to treatment with
antibiotics, was tested successfully in mice
as a means to provide a safe live challenge
in clinical trial, but it has not been pursued
further as a vaccine [28]. Leishmanization
has not been tested against disease caused
by species of Leishmania other than L. major;
furthermore, the degree of cross-protec-
tion provided has not been sufficiently
evaluated. It is noteworthy that epidemi-
ological evidence indicates that individuals
from Sudan with history of CL have lower
incidence of VL [29]. Okwor and Uzonna
[7] argue that vaccination with live-
parasite-based vaccines for CL would
induce effector and central memory cells.
The challenge will be to achieve attenua-
tion of live parasites without losing effica-
cy. In this regard, observations in animal
models indicate that antigen persistence
may be as important as the specific protein
or parasite component employed in a
vaccine [30].
Vector Saliva and Parasite Proteo-
Phosphoglycans: Role in Immunity
and in Vaccine Development
Salivary antigens of the vector are
important additional components of a
vaccine [20]. This aspect has received
little attention in spite of the fact that
salivary proteins from the vector are also
delivered to the host during natural trans-
mission of the pathogen, and, in at least
some cases, these proteins are immuno-
genic or immunomodulatory for the host
[31,32]. The rationales behind including
salivary antigens of the sand fly vector in
vaccines against the leishmaniases are 2-
fold and are not necessarily mutually
exclusive. If some of these salivary proteins
are immunosuppressants, they may also
compromise induction of protective im-
munity with Leishmania-derived antigens.
Thus, a vaccine may neutralize this immu-
nosuppressant activity. Conversely, several
salivary proteins are potent immunogens
and induce lymphocytic infiltration and
production of IFN-c and IL-12; this
reaction may set the local stage for a
protective anti-Leishmania immune re-
sponse. Sand fly bites induce hypersensi-
tivity reactions in many hosts, and the
problem of how to target sand fly salivary
proteins while avoiding these reactions
also needs to be addressed. Rogers and
colleagues [33] argue that parasite-secret-
ed proteo-phosphoglycans, rather than
vector saliva, are responsible for enhanced
disease following sand-fly-transmitted ver-
sus needle infection and are viable vaccine
targets. Proteo-phosphoglycans are regur-
gitated by phebotomines into the host,
where they activate host macrophages
through the alternative arginase pathway.
Arginase synthesizes polyamines, which
are essential growth factors for Leishmania
[34]. The neglect of the role of the vector
in vaccine development is reflected by the
fact that the efficacy of all but two [35,36]
experimental vaccines has been tested by
needle, rather than infected sand fly
challenge (see the Table S1). Kedzierski
and colleagues [20] call attention to the
influence of wound repair triggered by the
bite of the vector, a little-studied aspect of
resistance to leishmaniasis.
Antigens for Anti-Leishmaniasis
Vaccines: State of the Art
Most of the 25 vaccines licensed for use
in humans are effective because they drive
responses to many different targets on the
pathogens [37]. Therefore, the capacity to
Figure 3. Animal models used in leishmaniasis trials. Data are derived from Table S1, which contains a summary of all vaccines to date (both
experimental and in clinical use). Each color code reports the hosts in which Leishmania vaccines have been tested.
doi:10.1371/journal.pntd.0000943.g003
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a research agenda.
1. Vaccines That Employ Live Attenuated or GM Parasites or Antigens Delivered in the Form of Genetic (DNA) Vaccines
N How long does infection with attenuated or GM organisms need to persist in order for vaccines to be effective and produce long-term immunity (before the
infection is ‘‘cured’’ with drugs)?
N What kind of host response should be induced by a vaccine?
N Does Leishmania grown in chemically defined medium (serum-free due to safety concerns of vaccines made with cultured parasites) cause infection?
N How does the growth of live attenuated or GM parasites in axenic culture conditions impact their virulence?
N Why are GM parasites that lack virulence factors protective? What kind of response are they inducing, and what antigens are the vaccinated hosts recognizing?
N Do GM parasites, including knock-out parasites, over- or under-express proteins, including antigens of interest?
N What are thebiomarkers of safety for live attenuated orGM parasites? How do wevalidate biomarkers ofsafety, andwhat would be the appropriate modelto study that?
N Would leishmanization with innocuous species that express antigens of interest be protective?
N Safety and lack of toxicity of DNA vaccines and viral vectors are still unknown.
N Do we need adjuvants in combination of live attenuated or GM parasites as vaccine candidates? If so, what type, and when should they be used in the vaccination
scheme?
N What is the impact of vaccines that employ live attenuated or GM parasites for immunocompromised individuals?
2. The Role of Vectors and Vector Saliva in Modulating the Response to Vaccines and the Natural History of the Leishmaniases
N Is anti-vector immunity priming specific anti-Leishmania immunity?
N Can different levels of exposure to vector saliva (seasonal variations, host attraction, and kairomones) affect the type of immune response to saliva and/or to the
vector-borne pathogen?
N Can immunity to vectors have a herd effect on disease by affecting transmission and/or viability of vectors?
N What constitutes efficacy?
N More knowledge is needed on the natural history of the leishmaniases, especially if integrated control is necessary because of the lack of a vaccine with 100%
efficacy or difficulties in achieving 100% coverage.
N Further quantitative epidemiology studies and mathematical models, to predict the community effects of vaccination using a vaccine with ,100% efficacy or
,100% coverage, are needed.
N Vaccines should be evaluated by insect challenge.
N Should vaccines with attenuated live parasites be transmitted by the vector in order to confer herd immunity?
3. Antigen Discovery for Formulation of Vaccines
N What are the determinants of diverse biological behavior/characteristics of parasites of the same species?
N Considering that lesions in human tegumentary leishmaniasis (except diffuse CL) are the result of hypersensitivity reactions, the identification of pathoantigens is
necessary to understand the pathological process and preclude these molecules during antigen selection.
N Do we need more antigens (we already have 34 subunits; see Table S1)?
N What are good tools and strategies for discovering novel antigens?
N Should reverse vaccinology continue to be exploited?
N What are the criteria for defining antigens of interest when employing reverse vaccinology?
N Is the comparison of genomes of pathogens with those of nonpathogenic species useful?
N Are studies with single nucleotide polymorphisms on genetic variability/antigenic variation within host and parasite useful? Genotyping chips for humans and dogs
are available; a genotyping chip should be generated for Leishmania sp.
N Why are the antigens under evaluation giving insufficient protection? What is lacking in the host’s response? Do we need more adequate adjuvants for them? Do we
need more vaccination protocols, such as prime-boosting strategies? Are the antigens able to induce long-lasting protection?
N Why are some parasitic proteins immunogenic, while others are not? Can non-immunogenic proteins, as defined by patient sera, be protective antigens?
N What are the best delivery systems and regimens?
N What are the parasitic proteins that cause pathology? Should we focus on them for use as antigens?
N Antigens already under study should be better characterized concerning broadness of immunogenetic restriction, density and type of epitopes, role in parasite’s
biology, etc.
N More knowledge is needed about the species that cause mucocutaneous leishmaniasis and diffuse CL and the immune responses involved in these clinical outcomes.
N More knowledge is needed about the commonalities between the different causative agents of CL to explain why the different infections cause similar clinical
presentations.
4. Immune Responses of Natural Hosts and Models
N It is crucial to test vaccine candidates in different models using different species, and to test the effects of including salivary proteins in vaccines.
www.plosntds.org 5 March 2011 | Volume 5 | Issue 3 | e943respond to multiple antigens may be an
essential requisite of an efficacious vaccine.
This observation brings up the issue of
antigen discovery. As seen in Table S1, 34
subunits of Leishmania antigens are avail-
able, but they have not been evaluated as a
set of more than three components. Given
the complexity of the eukaryotic Leishmania
parasite, the fact that the response ob-
served following live vaccination or healed
infection in humans is poly-specific and
that immunization with a combination of
the antigens LmST11 and TSA, a poly-
protein vaccine, apparently confers the
best degree of protection so far in
nonhuman primates [38] suggests that an
increase in the known repertoire of
immunogenic antigens for this parasite is
necessary. The new sequencing technolo-
gies should facilitate this task. Table S1 is a
starting point, a database of vaccine
candidates similar to that created for
malaria [39]. A comparative analysis of
the genomes of Plasmodium vivax, P. falci-
parum, P. yoelii, and P. knowlesi [40] revealed
novel gene families and invasion pathways
in P. vivax. A similar advance with more
genomes of Leishmania parasites could
reveal alternative mechanisms of parasit-
ism and, thus, new targets for vaccines.
Another case in point is L. tarentolae,a
lizard pathogen that is nonpathogenic to
humans. It expresses a cysteine protease B,
lipophosphoglycan LPG3, and the leish-
manolysin GP63, which are virulence
genes of Leishmania species pathogenic for
humans. On the other hand, the A2 gene,
expressed by the L. donovani complex and
which promotes visceralization, is absent
in L. tarentolae [41]. L. tarentolae could play
the same role in leishmaniasis control that
vaccinia virus played in the eradication of
smallpox, where a species nonpathogenic
for humans induced protective immunity
against a related species of pathogen.
Finally, pathoantigens should be identified
to better understand the pathological
process, but also to preclude these mole-
cules during selection of vaccine candi-
dates and, if they are essential for
protective responses, to research strategies
to render them nonpathogenic.
The number of experimental vaccines
developed in the last 30 years that target
the different forms of leishmaniasis sur-
passes 100. These experimental vaccines
have undergone various stages of evalua-
tion and comprise antigens consisting of
whole live, attenuated, genetically modi-
fied, or killed parasites, or one or more
subunits or fusion proteins. They employ
different adjuvants, delivery systems, and
vectors. Finally, they have been evaluated
N Because of the difficulty of finding a good model of human leishmaniasis, before human trials, the nonhuman primate model appears to be an important option to
test candidate vaccines.
N What is the significance of subclinical infections? Are they useful for determining mechanisms of protection?
N DNA banks and genome-wide association studies with single nucleotide polymorphism chips can assist in determining the mechanisms behind the different
outcomes of clinical and subclinical infections with Leishmania; likewise whole-genome comparative expression profiling can dissect mechanisms of resistance and
susceptibility.
N Will T cells and antibodies from healthy hosts presenting with subclinical infections with Leishmania recognize different antigens/epitopes during expression cloning
for antigen discovery than T cells and antibodies from patients presenting clinically manifest disease? Are these antigens more useful to formulate vaccines?
N What kind of immune response is protective? What are the surrogate markers of protection?
N Is it important to avoid Th2/T regulatory–type responses to Leishmania and not just induce Th1/IFN-c responses?
N Are antibody responses part of a protective response?
N If antibodies are an important effector mechanism to be elicited by vaccines, how will current regulatory issues on vaccines for dogs be addressed?
N Do antibodies/immune responses exert selective pressure on antigens to undergo antigenic variation? Which antigens are they, and what is their role in the
parasite’s biology? Is it an important role?
N What is the role of antigen processing in mounting protective immune responses?
N What is the role of neutrophils in protection from or susceptibility to Leishmania?
N What is the role of co-infections and nutritional status in the immune responses to Leishmania and to vaccines?
N What is the role of the host’s genetic background in susceptibility to clinical manifestations of infections with Leishmania and responses to vaccines?
5. Models and Clinical Trials
N Uniform challenges in both models and humans need to be implemented to test the different antigens in a comparative fashion.
N Again, what constitutes protection/efficacy?
N What are the surrogate markers of protection, and how are they measured?
N Crude Leishmania preparations for leishmanin (Montenegro) skin tests and first generation vaccines are subject to batch-to-batch variation, an issue which needs to
be urgently addressed.
6. Funding for Vaccine Development
N From the points mentioned herein, it is important to recommend funding for primate facilities.
N Funding for access to good manufacturing processes facilities and for sand fly experiments in vaccine development is also important.
7. Sharing Information
N The LeishNet Web site (http://leishnet.net) should be reissued. A Leish-L list of E-mails linked to more modern tools as well as to an area specific for leishmaniasis
vaccines, with an interactive approach similar to Wikipedia, should be constructed.
doi:10.1371/journal.pntd.0000943.t001
Table 1. Cont.
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humans. Table S1 (an interactive version
of this table is available at http://www.
leishvaccines.net) and Figures 1–3 sum-
marize all of these efforts, and the
numbers they depict attest to the fact that
vaccinology is still an imprecise science
and can be bewildering to authorities and
planners.
Concluding Remarks
The main questions raised during
debates at the International Symposium
on Leishmaniasis Vaccines are summa-
rized in Table 1. Except when specifically
noted, the questions addressed issues
concerning all of the leishmaniases. They
addressed live attenuated or genetically
modified (GM) parasites, the role of
vectors, further antigen discovery, and
elucidation of protective immunity for
formulation of vaccines, models and clin-
ical trials, funding policies, and dissemina-
tion of information on all these issues, on
which the development of vaccines for the
leishmaniases depends.
Funding agencies must be persuaded
that the profile of the leishmaniases is
shifting and that a concerted action is
needed with new scientific approaches. A
strategic plan is needed to attain truly
efficacious vaccines against the leishman-
iases. The first bottleneck to overcome is
caused by scientific gaps; therefore, a call
for grant proposals should focus on a few
scientific questions and research priorities
in vaccinology for VL and CL that are
potentially very informative. Proposals
should ideally be executed as a network
in order to maximize existing information
generated by individual groups and to
generate new insights. The research pri-
orities could be validated through consul-
tations with participants in the discussion
group that the Working Group has set
up (http://groups.google.com.br/group/
leishvaccines-l) during a fixed period of
time, six months. In principle these
research priorities might address the
following:
N The role of parasite persistence in
protective immunity and live versus
killed/subunit vaccines in order to
define (i) a product profile for VL
and CL and (ii) whether it is valid to
improve leishmanization for CL;
N The role of immunity to vector saliva
in immunity against different species
of Leishmania and in composition of
vaccines;
N The significance and immunological
profile of the hosts who are able to
maintain subclinical infections and
their role in obtaining biomarkers of
resistance and protective immunity;
N Further application of genomic ap-
proaches for (i) identifying virulence
factors in different species of Leishmania
and (ii) antigen discovery;
N Re-formulation of a previously tested
subunit vaccines that include novel
antigens, including antigens of the 30
subunits previously identified by dif-
ferent groups (Table S1), and/or new
adjuvants.
Conceptual and technological advances
in immunology, parasitology, genetics,
genomics, and bioinformatics have in-
creased our capacity to address the
research priorities with a more effective
systemic approach to the vector–Leishman-
ia–host interface. However, these advances
do not affect the constraints that spring
from the placement of political will and
personal scientific convictions. The size of
this task and the seriousness of the
problem represented by these neglected
diseases warrant a large collaborative
effort. At least 30 vaccine subunits (listed
in the Table S1) have been tested with
relative success by several different groups.
If a multicomponent vaccine is a sine qua
non condition for achieving an effective
vaccine, many of these antigens will
probably be part of the composition. In
this case, the issue of intellectual property
becomes an significant barrier for attract-
ing companies willing to develop, manu-
facture, and market a vaccine. The
funding agencies and grantees must devise
a solution that is fair for all interested
parties, including the patients.
An example in science where competing
groups (with large financial interests at
stake) eventually united and then achieved
a common goal is seen in the cloning of
the gene causing cystic fibrosis. In contrast
to the the situation for patients with
neglected leishmaniases, patients with
cystic fibrosis and their families count on
the active Cystic Fibrosis Foundation,
incorporated in 1955, which created a
network of research centers and a research
program in 1980, the same time that
efforts began for developing subunit vac-
cines for Leishmania. In less than nine years,
in the pre-genomics era, the defective
cystic fibrosis gene and its protein product
were described. Presently, more than 30
drugs that modulate the cystic fibrosis
gene product itself are in the pipeline,
including phase 3 trials. Individuals at risk
for developing leishmaniasis need a similar
voice and concerted action.
Supporting Information
Table S1 A survey of antigens, adju-
vants, delivery systems, and models em-
ployed for developing vaccines for the VLs
and CLs.
Found at: doi:10.1371/journal.pntd.
0000943.s001 (0.99 MB DOC)
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